Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
2,226
Views
5
CrossRef citations to date
0
Altmetric
Letter to the Editor

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers

Diego Orsinia Clinical Dermatology Unit - San Gallicano Dermatological Institute IRCCS, Rome, ItalyView further author information
,
Luigi Gargiulob Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy;c Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Luciano Ibbab Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy;c Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyCorrespondence[email protected]
View further author information
,
Ruggero Cascio Ingurgiob Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy;c Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Mario Valentib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy;c Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
,
Chiara Peruginib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
,
Alessia Pacificoa Clinical Dermatology Unit - San Gallicano Dermatological Institute IRCCS, Rome, ItalyView further author information
,
Fabio S. Maramaod UOSD di Dermatologia, Fondazione Policlinico Tor Vergata, Università degli studi di Roma Tor VergataView further author information
,
Pasquale Frascionee Dermatology Oncology Unit– San Gallicano Dermatological Institute IRCCS, Rome, ItalyView further author information
,
Antonio Costanzob Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy;c Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information
&
Alessandra Narcisib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
 show all
Article: 2220849 | Received 09 Apr 2023, Accepted 24 Apr 2023, Published online: 08 Jun 2023

References

  • Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1–4.
  • Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatolog Treat. 2018;29(8):754–760.
  • Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2009;60(6):962–971.
  • Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.
  • Canal-García E, Bosch-Amate X, Belinchón I, et al. Nail psoriasis. Psoriasis ungueal. Actas Dermosifiliogr. 2022;113(5):481–490.
  • Balak DMW, Gerdes S, Parodi A, et al. Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. Dermatol Ther . 2020;10(4):589–613.
  • Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in -to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661.
  • Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of Risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther . 2022;12(10):2309–2324.
  • 17. European Medicines Agency. Skyrizi (risankizumab): summary of product characteristics. 2019. [cited 2023, April 04]. http://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi.
  • Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study [published online ahead of print, 2023 Apr 3]. J Dermatolog Treat. 2023;34(1):2199108.
  • Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of Tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. JCM. 2022;11(9):2631. Published 2022 May 7.
  • Guenther L, Potts Bleakman A, Weisman J, et al. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol. 2020;100(1):adv00006. Published 2020 Jan 7.
  • Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.
  • Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2023;37(1):93–103.
  • Mastorino L, Susca S, Megna M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35(5):e15378.
  • Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813–2820.
  • Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS) [published online ahead of print, 2023 Jan 25]. Acad Dermatol Venereol. 2023;37(5):1017–1027.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.